Financial reports
10-K
2023 FY
Annual report
28 Mar 24
10-Q
2023 Q3
Quarterly report
14 Nov 23
10-Q
2023 Q2
Quarterly report
14 Aug 23
10-Q
2023 Q1
Quarterly report
15 May 23
10-K
2022 FY
Annual report
31 Mar 23
10-Q
2022 Q3
Quarterly report
14 Nov 22
10-Q
2022 Q2
Quarterly report
11 Aug 22
10-Q
2022 Q1
Quarterly report
12 May 22
10-K
2021 FY
Annual report
28 Mar 22
10-Q
2021 Q3
Quarterly report
15 Nov 21
Current reports
8-K
Fortress Biotech Reports 2023 Financial Results and Recent Corporate Highlights
28 Mar 24
8-K
Departure of Directors or Certain Officers
26 Jan 24
8-K
Fortress Biotech Announces Pricing of $11 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
3 Jan 24
8-K
Fortress Biotech Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights
14 Nov 23
8-K
Fortress Biotech Announces Launch of Proposed Public Offering
14 Nov 23
8-K
Other Events
26 Oct 23
8-K
Fortress Biotech Announces Reverse Stock Split
10 Oct 23
8-K
Fortress Biotech Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights
14 Aug 23
8-K
Departure of Directors or Certain Officers
23 Jun 23
8-K
Entry into a Material Definitive Agreement
16 Jun 23
Registration and prospectus
424B3
Prospectus supplement
5 Apr 24
424B5
Prospectus supplement for primary offering
2 Jan 24
424B5
Prospectus supplement for primary offering
13 Nov 23
424B5
Prospectus supplement for primary offering
9 Nov 23
S-8
Registration of securities for employees
29 Sep 23
S-8
Registration of securities for employees
29 Sep 23
424B5
Prospectus supplement for primary offering
26 May 23
S-3/A
Shelf registration (amended)
7 Apr 23
S-3
Shelf registration
10 Feb 23
424B5
Prospectus supplement for primary offering
9 Feb 23
Proxies
DEFA14A
Additional proxy soliciting materials
5 Apr 24
DEF 14A
Definitive proxy
5 Apr 24
DEFA14A
Additional proxy soliciting materials
25 Aug 23
DEF 14A
Definitive proxy
25 Aug 23
PRE 14A
Preliminary proxy
15 Aug 23
DEF 14A
Definitive proxy
28 Apr 23
DEFA14A
Additional proxy soliciting materials
28 Apr 23
DEF 14A
Definitive proxy
13 Mar 23
PRE 14A
Preliminary proxy
3 Mar 23
DEFA14A
Additional proxy soliciting materials
17 May 22
Other
UPLOAD
Letter from SEC
30 Nov 23
CORRESP
Correspondence with SEC
26 Oct 23
UPLOAD
Letter from SEC
27 Sep 23
CORRESP
Correspondence with SEC
18 Jul 23
UPLOAD
Letter from SEC
3 Jul 23
EFFECT
Notice of effectiveness
14 Apr 23
CORRESP
Correspondence with SEC
13 Apr 23
UPLOAD
Letter from SEC
15 Feb 23
EFFECT
Notice of effectiveness
2 Dec 21
EFFECT
Notice of effectiveness
5 Nov 21
Ownership
SC 13D/A
AVENUE THERAPEUTICS, INC.
17 Apr 24
4
AVENUE THERAPEUTICS, INC.
17 Apr 24
4
David Jin
2 Apr 24
SC 13D/A
Checkpoint Therapeutics, Inc.
22 Mar 24
4
Checkpoint Therapeutics, Inc.
22 Mar 24
SC 13G/A
Nantahala Capital Management, LLC
14 Feb 24
4
LINDSAY A MD ROSENWALD
9 Jan 24
4
Lucy Lu
3 Jan 24
4
Kevin Lorenz
3 Jan 24
4
J JAY LOBELL
3 Jan 24